Information Journal Paper
APA:
Copy. (2017). A phase II study of antibody-drug conjugate, TAK-264 (MLN0264) in previously treated patients with advanced or metastatic pancreatic adenocarcinoma expressing guanylyl cyclase C. INVESTIGATIONAL NEW DRUGS, 35(5), 634-641. SID. https://sid.ir/paper/759156/en
Vancouver:
Copy. A phase II study of antibody-drug conjugate, TAK-264 (MLN0264) in previously treated patients with advanced or metastatic pancreatic adenocarcinoma expressing guanylyl cyclase C. INVESTIGATIONAL NEW DRUGS[Internet]. 2017;35(5):634-641. Available from: https://sid.ir/paper/759156/en
IEEE:
Copy, “A phase II study of antibody-drug conjugate, TAK-264 (MLN0264) in previously treated patients with advanced or metastatic pancreatic adenocarcinoma expressing guanylyl cyclase C,” INVESTIGATIONAL NEW DRUGS, vol. 35, no. 5, pp. 634–641, 2017, [Online]. Available: https://sid.ir/paper/759156/en